ATE524739T1 - Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten - Google Patents

Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten

Info

Publication number
ATE524739T1
ATE524739T1 AT03736436T AT03736436T ATE524739T1 AT E524739 T1 ATE524739 T1 AT E524739T1 AT 03736436 T AT03736436 T AT 03736436T AT 03736436 T AT03736436 T AT 03736436T AT E524739 T1 ATE524739 T1 AT E524739T1
Authority
AT
Austria
Prior art keywords
treatment
adjuvant
upa
pai
subject
Prior art date
Application number
AT03736436T
Other languages
English (en)
Inventor
Nadia Harbeck
Ronald Kates
Manfred Schmitt
John Foekens
Original Assignee
American Diagnostica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Diagnostica Inc filed Critical American Diagnostica Inc
Application granted granted Critical
Publication of ATE524739T1 publication Critical patent/ATE524739T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
AT03736436T 2002-02-13 2003-02-13 Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten ATE524739T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35692802P 2002-02-13 2002-02-13
US40231102P 2002-08-09 2002-08-09
PCT/US2003/004538 WO2003082072A2 (en) 2002-02-13 2003-02-13 Methods for selecting treatment regimens and predicting outcomes in cancer patients

Publications (1)

Publication Number Publication Date
ATE524739T1 true ATE524739T1 (de) 2011-09-15

Family

ID=28678149

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03736436T ATE524739T1 (de) 2002-02-13 2003-02-13 Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten

Country Status (7)

Country Link
US (3) US20060084056A1 (de)
EP (3) EP1563302B1 (de)
AT (1) ATE524739T1 (de)
AU (2) AU2003237779B2 (de)
CA (1) CA2476352A1 (de)
ES (1) ES2373547T3 (de)
WO (1) WO2003082072A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210979A1 (en) * 2003-01-13 2006-09-21 Lily Yang Methods of detecting gene expression in normal and cancerous cells
US8168568B1 (en) 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
US20050244893A1 (en) * 2004-04-16 2005-11-03 Wyeth Novel method for determination of plasminogen activator inhibitor
WO2006028655A2 (en) * 2004-08-13 2006-03-16 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
FR2886946B1 (fr) * 2005-06-09 2007-08-10 Biomerieux Sa Procede pour le diagnoctic/pronostic du cancer du sein
US20070156453A1 (en) * 2005-10-07 2007-07-05 Brainlab Ag Integrated treatment planning system
US8105602B2 (en) 2006-12-08 2012-01-31 Tactic Pharma, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
WO2010073248A2 (en) * 2008-12-24 2010-07-01 Rosetta Genomics Ltd. Gene expression signature for classification of tissue of origin of tumor samples
EP2093567A1 (de) * 2008-02-21 2009-08-26 Pangaea Biotech, S.A. Brca1-mRNA-Expressionsebenen zur Vorhersage der Überlebensaussichten von mit neoadjuvanter Chemotherapie behandelten Brustkrebspatienten
US20100304373A1 (en) * 2008-08-14 2010-12-02 Ricciardi Robert P Methods for Assessing the Susceptibility of a Human to Diminished Health and Wellness
US20110195848A1 (en) * 2010-01-08 2011-08-11 Roopra Avtar S Gene expression and breast cancer
JP6002379B2 (ja) * 2011-11-29 2016-10-05 シスメックス株式会社 癌の再発リスクの判定方法及びその利用
US10648034B2 (en) 2012-04-09 2020-05-12 Yale University Compositions and methods for diagnosing and treating meningioma
US20140081659A1 (en) 2012-09-17 2014-03-20 Depuy Orthopaedics, Inc. Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking
WO2014089241A2 (en) * 2012-12-04 2014-06-12 Caris Mpi, Inc. Molecular profiling for cancer
EP3028052B1 (de) * 2013-08-01 2017-11-01 Fundación Pública Andaluza Progreso Y Salud Verfahren zur vorhersage der behandlungsreaktion und test zur sicheren anwendung von mesenchymalen stammzellen bei entzündungskrankheiten
US20190147986A1 (en) * 2016-05-17 2019-05-16 Abraxis Bioscience, Llc Methods for assessing neoadjuvant therapies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1992006180A1 (en) 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
CA2103064A1 (en) 1991-05-14 1992-11-15 George Y. Wu Targeted delivery of genes encoding immunogenic proteins
EP0587738B1 (de) 1991-06-05 2000-08-23 University Of Connecticut Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
DK85193D0 (da) * 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US5449761A (en) 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
US5635493A (en) 1993-12-01 1997-06-03 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics
AU726406B2 (en) * 1996-04-12 2000-11-09 Regents Of The University Of Michigan, The Mutant plasminogen activator-inhibitor type 1 (PAI-1) and uses thereof
US5816397A (en) 1997-01-21 1998-10-06 Ogio International, Inc. Golf club carrying apparatus
DE60326214D1 (de) * 2002-03-01 2009-04-02 Siemens Healthcare Diagnostics Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten

Also Published As

Publication number Publication date
EP2302385B1 (de) 2014-12-03
WO2003082072A2 (en) 2003-10-09
AU2003237779A1 (en) 2003-10-13
EP1563302A4 (de) 2007-12-12
EP1563302A2 (de) 2005-08-17
EP2360476B1 (de) 2017-10-25
AU2008203388A1 (en) 2008-08-21
US20060084056A1 (en) 2006-04-20
CA2476352A1 (en) 2003-10-09
AU2003237779B2 (en) 2008-06-26
EP2360476A1 (de) 2011-08-24
US20180282822A1 (en) 2018-10-04
WO2003082072A3 (en) 2005-06-16
EP1563302B1 (de) 2011-09-14
US20190233899A1 (en) 2019-08-01
EP2302385A1 (de) 2011-03-30
ES2373547T3 (es) 2012-02-06

Similar Documents

Publication Publication Date Title
ATE524739T1 (de) Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten
Mendenhall et al. Giant cell tumor of bone
AU2003260966A8 (en) Genes and polypeptides relating to human pancreatic cancers
HK1203568A1 (en) Gene expression profiling in biopsied tumor tissues
Lippman New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK
Langendijk et al. Radiotherapy of squamous cell carcinoma of the nasal vestibule
Murakami et al. Increase of IL-12 following reconstruction for total en bloc spondylectomy using frozen autografts treated with liquid nitrogen
Wisniewski et al. The effect of radiotherapy and hormone therapy on osteopontin concentrations in prostate cancer patients
Chen et al. Retrospective study of selective neck dissection versus radical neck dissection as salvage therapy for patients with recurrent nasopharyngeal squamous cell carcinoma
WO2001004343A3 (en) A method for determining the prognosis of cancer patients by measuring levels of bag expression
Hurtado-López et al. Regional node distribution in papillary thyroid cancer with microscopic metastasis
Kallel et al. Deep venous thrombosis related to protein S deficiency revealing celiac disease
Persson et al. Deep inspiration breath hold compliance in radiation therapy for locally advanced lung cancer
WO2002099421A3 (en) Specific microarrays for breast cancer screening
Wozniak et al. The effect of combined therapy on activity of cathepsin D and alpha-1-antitrypsin in the blood serum of women with cervical cancer
Dong et al. A Nomogram to Predict Locoregional Recurrence after Surgery and Postoperative Adjuvant Radiation Therapy for Primary Mucosal Melanoma of the Head and Neck
Hinchcliff et al. Adverse events and responses in patients with recurrent ovarian cancer undergoing early-phase immune checkpoint inhibitor clinical trials
Liang et al. Outcomes of MR-guided stereotactic body radiotherapy (SBRT) or yttrium-90 transarterial radioembolization for hepatocellular carcinoma treated at an urban liver transplant center
Kotromanović THE DIFFERENCE IN TIME UNTIL THE APPEARANCE OF RECIDIVE OR METASTASIS MANIFESTATION AT PATIENTS CURED AGAINST COLORECTAL CANCER DEPENDING ON THE POSITION IN THE LEFT OR RIGHT COLON
Kaplan et al. Enzalutamide Monotherapy with EBRT for Intermediate Risk Prostate Cancer. A Phase 2 Study
Barot et al. A Single Institution Retrospective Analysis of Adult Head & Neck Rhabdomyosarcoma (HN RMS) from 1984-2017
Gill et al. Implication of Adjuvant Radiation Therapy and Dose-Response Relationship for Margin-Positive Vulvar Squamous Cell Carcinoma
Beniey et al. Use of Intraoperative Radioguidance in Recurrent Merkel Carcinoma
Binder et al. Real-world plaque brachytherapy clinical practices among Ocular Oncology Study Consortium treatment centers
Moran et al. PSA outcomes in a single institution, prospective randomized 131Cs/125I permanent prostate brachytherapy trial

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties